Abstract:Anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase in the insulin receptor superfamily, was first identified as a chromosomal rearrangement (NPM-ALK fusion gene) in anaplastic large cell lymphoma (ALCL). Alternate EML4-ALK gene translocation has been detected in a subset of non-small cell lung cancers (NSCLC) and single point mutations in ALK have been identified in a subset of neuroblastomas. Whereas expression of ALK is limited in normal adult human tissues, genetic studies indicate that aberrant expression of ALK is a key driver in these tumor types, which highlights ALK as an important potential target in treating human tumors. The high sequence homology of ALK with other members of the insulin receptor superfamily, presents a significant challenge in the design of ALK-selective inhibitors. Here we report the identification of a series of potent compounds that inhibit ALK both in vitro and in vivo, while maintaining >60 and 400-fold selectivity over the highly homologous insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor tyrosine kinase (IRK), respectively. A representative member from this series inhibited the kinase activity of ALK, IGF-1R, and IRK with IC50s of 0.58, 38, and 262 nM, respectively, and inhibited the viability of Karpas-299 and SU-DHL-1 cells (ALCL cell lines expressing NPM-ALK) with IC50s of 32 and 8 nM, respectively. In Karpas-299 cells, inhibition of viability directly correlated with decreased cellular phosphorylation of NPM-ALK. In NCI-H3122 cells, a NSCLC cell line expressing an EML4-ALK fusion gene, a 30 nM concentration of the same compound inhibited EML4-ALK phosphorylation and cell viability by approximately 50%. For cells that do not express ALK, the IC50s for inhibition of proliferation in several control ALCL and NSCLC cell lines were >1000 nM and the IC50 for phosphorylation of IRK in hepatoma H4IIE cells was >10,000 nM. In vivo, daily oral administration of this specific lead compound to mice bearing subcutaneous xenografts of Karpas-299 cells elicited a dose-dependent antitumor effect, with near-complete tumor regression observed at the highest doses of 50 and 100 mg/kg. In rats, oral doses that achieved plasma levels that were efficacious in the Karpas-299 mouse model had no effect on either insulin or glucose levels. In conclusion, these data demonstrate that despite the high sequence homology among members of the insulin receptor superfamily, identification of ALK-selective compounds is possible and supports the clinical evaluation of such compounds in patients with ALK-driven tumors. Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 3738.

Discovery Of Cj-2360 As A Potent And Orally Active Inhibitor Of Anaplastic Lymphoma Kinase Capable Of Achieving Complete Tumor Regression

Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib.

Discovery of (R)-5-((5-(1-methyl-1h-pyrazol-4-yl)-4-(methylamino)pyrimidin-2-yl)amino)-3-(piperidin-3-yloxy)picolinonitrile, a Novel CHK1 Inhibitor for Hematologic Malignancies.

Abstract #3738: Discovery of Potent and Selective Orally Active Inhibitors of Anaplastic Lymphoma Kinase (ALK)

CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers

Design and synthesis of novel selective anaplastic lymphoma kinase inhibitors

Discovery of 2-Aminopyrimidine Derivatives As Potent Dual FLT3/CHK1 Inhibitors with Significantly Reduced Herg Inhibitory Activities.

Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation

Discovery of Potent and Effective Inhibitors Containing Sulfoxide Structures Targeting EML4-ALK Rearrangement and EGFR Mutant Non-Small Cell Lung Cancer

Discovery of 5-trifluoromethyl-2-aminopyrimidine derivatives as potent dual inhibitors of FLT3 and CHK1

Discovery of novel anaplastic lymphoma kinase (ALK) and histone deacetylase (HDAC) dual inhibitors exhibiting antiproliferative activity against non-small cell lung cancer

Synthesis and Anti-Tumor Efficacy of Novel 2, 4-Diarylaminopyrimidine Derivatives Bearing N-(3-pyridinylmethyl) Urea Moiety As Anaplastic Lymphoma Kinase Inhibitors.

Discovery of JAB-3312, a Potent SHP2 Allosteric Inhibitor for Cancer Treatment

Abstract B99: Discovery of 2,4-Diarylaminopyrimidine SOMCL-12-81 As a Potent Inhibitor Targeting Both Wild and Mutant ALK Kinases.

Pharmacologic characterization of CT-711, a novel dual inhibitor of ALK and c-Met

A novel lead compound CM-118: antitumor activity and new insight into the molecular mechanism and combination therapy strategy in c-Met- and ALK-dependent cancers.

Design, Synthesis and Pharmacological Evaluation of 2-(Thiazol-2-amino)-4-arylaminopyrimidines As Potent Anaplastic Lymphoma Kinase (ALK) Inhibitors

Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC.

Discovery of 3-Aminopyrazole Derivatives As New Potent and Orally Bioavailable AXL Inhibitors.

A Novel Lead Compound CM-118